CD33 and lung carcinoma: Administration of Cucurbitacin B (CuB), a selective inhibitor of the JAK2/STAT3 pathway, to patients with advanced lung cancers decreased peripheral blood levels of Lin-HLA-DR-CD33+ immature myeloid cells and increased peripheral blood levels of Lin-HLA-DR+CD33+ mature myeloid cells compared with baseline levels.